Key result
Successful transcatheter mitral valve repair reduced in-hospital mortality in patients with cardiogenic shock and significant mitral regurgitation (HR 0.36; 95% CI 0.13-0.98; p=0.04).
Why the study?
Patients in cardiogenic shock with severe MR have a poor prognosis with conventional therapy, and while TMVr is increasingly used acutely due to its safety profile, its efficacy remains unknown.
Does successful transcatheter mitral valve repair (TMVr) reduce mortality in patients with cardiogenic shock and significant mitral regurgitation who are not surgical candidates?
Population
141 patients with cardiogenic shock and moderate-to-severe (3+) or severe (4+) MR not eligible for surgery
Comparison
TMVr outcomes stratified by device success
Design
Multicenter collaborative patient-level analysis across 14 institutions
Follow-up
one year
Authors
Loading...
Hypothesis-generating for TMVr in cardiogenic shock with MR; prospective randomized trials needed before clinical adoption.
Cohort (n=141)
Yes
Does successful transcatheter mitral valve repair (TMVr) reduce mortality in patients with cardiogenic shock and significant mitral regurgitation who are not surgical candidates?
Hazard Ratio: 0.36 (95% CI 0.13–0.98)
p-value: p=0.04
In high-risk patients with cardiogenic shock and significant mitral regurgitation, successful transcatheter mitral valve repair is associated with improved short- and intermediate-term survival.
Jung et al. (2020) conducted a cohort in Cardiogenic shock and significant mitral regurgitation (n=141). Successful transcatheter mitral valve repair (TMVr) vs. Unsuccessful TMVr was evaluated on In-hospital mortality (HR 0.36, 95% CI 0.13-0.98, p=0.04). Successful transcatheter mitral valve repair reduced in-hospital mortality in patients with cardiogenic shock and significant mitral regurgitation (HR 0.36; 95% CI 0.13-0.98; p=0.04).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: